SEC Form 4 · accession 0001763494-26-000007

Travere Therapeutics, Inc. · TVTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Eric M Dube

Officer — CHIEF EXECUTIVE OFFICER · Director

Period of report

Sep 15, 2026

Accepted (ET)

Sep 17, 2026 · 9:31 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001438533

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 15, 2026	M	95,666	$23.34	A	528,552	D
Common Stock^F2	Sep 15, 2026	S	63,498	$61.9945	D	465,054	D
Common Stock^F3	Sep 15, 2026	S	28,796	$62.6553	D	436,258	D
Common Stock^F4	Sep 15, 2026	S	3,102	$63.6434	D	433,156	D
Common Stock	Sep 15, 2026	S	270	$65.31	D	432,886	D
Common Stock	Sep 16, 2026	M	195,841	$23.34	A	628,727	D
Common Stock^F5	Sep 16, 2026	S	99,716	$63.2593	D	529,011	D
Common Stock^F6	Sep 16, 2026	S	96,125	$63.6389	D	432,886	D
Common Stock	Sep 17, 2026	M	108,493	$23.34	A	541,379	D
Common Stock^F7	Sep 17, 2026	S	101,691	$64.5866	D	439,688	D
Common Stock^F8	Sep 17, 2026	S	6,802	$64.9508	D	432,886	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee stock option (right to buy)^F9	$23.34	Sep 15, 2026	M	95,666	D	—	Jan 4, 2029	Common Stock	95,666	304,334	D
Employee stock option (right to buy)^F9	$23.34	Sep 16, 2026	M	195,841	D	—	Jan 4, 2029	Common Stock	195,841	108,493	D
Employee stock option (right to buy)^F9	$23.34	Sep 17, 2026	M	108,493	D	—	Jan 4, 2029	Common Stock	108,493	0	D

Explanation of responses

F1This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F9The stock option is fully vested and exercisable.